May 31, 2015Open Access

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).

Read Full Paperexternally

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Brahmer et al. (Sun,) studied this question.

synapsesocial.com/papers/69d80ac53eff0c9dfaae31e7 https://doi.org/https://doi.org/10.1056/nejmoa1504627

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial2015 · 1,429 citations
2Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer2015 · 1,193 citations
3Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy.2014 · 17 citations
4Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)2014 · 72 citations
5Pathology of lung cancer2002 · 652 citations

AI से पूछें

Bookmark

View Full Paper